Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 8/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 8/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.42 |
| ▸ | CMA1 | P23946 | 7/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8972436 | 0.79 | RAB9A (0.52) | CTSGCTRB1PRSS1CMA1SMN1; SMN2 | |
| SCHEMBL6606965 | 0.79 | CTSG (0.43) | CTSGCTRB1PRSS1CMA1P2RY12 | |
| SCHEMBL3422512 | 0.78 | CTSG (0.43) | CTSGCTRB1PRSS1CMA1SMN1; SMN2 | |
| SCHEMBL4650932 | 0.77 | CASP3 (0.54) | CYP2D6KLK5 | |
| SCHEMBL4650929 | 0.77 | CASP3 (0.54) | CYP2D6KLK5 | |
| SCHEMBL5494468 | 0.74 | CTSD (0.51) | KLK5 | |
| SCHEMBL311493 | 0.74 | ELANE (0.39) | CYP2D6KLK5 | |
| SCHEMBL311492 | 0.74 | ELANE (0.39) | CYP2D6KLK5 | |
| SCHEMBL14269200 | 0.74 | SYK (0.52) | CTRB1KLK5CTSK | |
| SCHEMBL6606570 | 0.73 | CTSG (0.43) | CTSGCTRB1PRSS1CMA1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1163208-B1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6632962-B2 | N-(2-carboxy-1-haloacetylethyl)arylamide derivatives as inhibitors of caspase and cellular apoptosis. | VERTEX PHARMACEUTICALS INCORPORATED | 2003-10-14 | — | — | US | disclosed |
| US-20020132833-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-09-19 | — | — | US | disclosed |
| EP-1163208-A4 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2002-07-03 | — | — | EP | disclosed |
| EP-1163208-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2001010383-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132833-A1 | Caspase inhibitors and uses thereof | CASP1, CASP3, CASP7 | CTSG 216/4885CTRB1 259/4885PRSS1 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.